Conmed Corp Financials
This page shows Conmed Corp (CNMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
Conmed Corp has an operating margin of 7.5%, meaning the company retains $7 of operating profit per $100 of revenue. This results in a moderate score of 37/100, indicating healthy but not exceptional operating efficiency. This is down from 15.3% the prior year.
Conmed Corp's revenue declined 99.9% year-over-year, from $1.3B to $1.4M. This contraction results in a growth score of 0/100.
Conmed Corp carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.14, Conmed Corp holds $2.14 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 65/100.
Conmed Corp has a free cash flow margin of 11.0%, earning a moderate score of 55/100. The company generates positive cash flow after capital investments, but with room for improvement.
Conmed Corp generates a 4.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 18/100. This is down from 13.8% the prior year.
Conmed Corp scores 602.12, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.3B) relative to total liabilities ($1.3M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Conmed Corp passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Conmed Corp generates $3.63 in operating cash flow ($171K OCF vs $47K net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Conmed Corp earns $3.3 in operating income for every $1 of interest expense ($103K vs $31K). This adequate coverage means the company can meet its interest obligations, but has limited cushion if earnings fall.
Key Financial Metrics
Conmed Corp generated $1.4M in revenue in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Conmed Corp's EBITDA was $120K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 100.0% from the prior year.
Conmed Corp generated $151K in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 99.9% from the prior year.
Conmed Corp reported $47K in net income in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
Conmed Corp earned $1.51 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 64.5% from the prior year.
Conmed Corp held $41K in cash against $40K in long-term debt as of fiscal year 2025.
Conmed Corp paid $0.80 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Conmed Corp had 31M shares outstanding in fiscal year 2025. This represents a decrease of 0.2% from the prior year.
Conmed Corp's gross margin was 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.5 percentage points from the prior year.
Conmed Corp's operating margin was 7.5% in fiscal year 2025, reflecting core business profitability. This is down 7.9 percentage points from the prior year.
Conmed Corp's net profit margin was 3.4% in fiscal year 2025, showing the share of revenue converted to profit. This is down 6.7 percentage points from the prior year.
Conmed Corp's ROE was 4.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 9.2 percentage points from the prior year.
Conmed Corp invested $56K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
Conmed Corp invested $20K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 99.8% from the prior year.
CNMD Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $337.9M-1.3% | $342.3M+6.6% | $321.3M-7.1% | $345.9M+4.2% | $332.1M+6.3% | $312.3M-4.5% | $327.0M+7.4% | $304.6M |
| Cost of Revenue | $171.8M+11.5% | $154.0M+7.3% | $143.5M-2.8% | $147.6M-0.5% | $148.4M+5.7% | $140.3M-3.1% | $144.9M+6.1% | $136.5M |
| Gross Profit | $166.1M-11.8% | $188.3M+5.9% | $177.8M-10.4% | $198.3M+8.0% | $183.7M+6.8% | $172.0M-5.6% | $182.2M+8.4% | $168.1M |
| R&D Expenses | $13.9M-1.7% | $14.1M+9.2% | $12.9M-1.7% | $13.2M-6.5% | $14.1M+3.7% | $13.6M-3.1% | $14.0M+12.5% | $12.5M |
| SG&A Expenses | $140.3M+3.2% | $136.0M-8.6% | $148.8M+12.2% | $132.7M+8.3% | $122.5M-0.7% | $123.4M+4.6% | $118.0M-5.9% | $125.3M |
| Operating Income | $11.9M-68.9% | $38.2M+139.1% | $16.0M-69.6% | $52.5M+11.4% | $47.1M+34.5% | $35.0M-30.2% | $50.2M+65.6% | $30.3M |
| Interest Expense | $7.6M-2.8% | $7.8M-5.6% | $8.3M-6.5% | $8.9M-7.7% | $9.6M0.0% | $9.6M+0.9% | $9.5M-5.1% | $10.0M |
| Income Tax | $1.4M-83.4% | $8.5M+419.4% | $1.6M-83.5% | $9.9M+31.2% | $7.5M+32.0% | $5.7M-25.0% | $7.6M+71.3% | $4.4M |
| Net Income | $2.9M-86.7% | $21.4M+254.9% | $6.0M-82.1% | $33.8M+12.6% | $30.0M+52.1% | $19.7M-40.4% | $33.1M+108.8% | $15.8M |
| EPS (Diluted) | $0.09-87.0% | $0.69+263.2% | $0.19-82.6% | $1.09+13.5% | $0.96+52.4% | $0.63-40.0% | $1.05+110.0% | $0.50 |
CNMD Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.3B-0.3% | $2.3B+1.3% | $2.3B-0.4% | $2.3B+0.9% | $2.3B-1.0% | $2.3B+0.4% | $2.3B-1.1% | $2.3B |
| Current Assets | $662.2M+0.7% | $657.8M+2.9% | $639.0M-0.2% | $640.0M+2.6% | $623.8M-1.9% | $635.7M+3.3% | $615.6M-1.6% | $625.6M |
| Cash & Equivalents | $38.9M+14.7% | $33.9M-4.4% | $35.5M+45.1% | $24.5M-15.3% | $28.9M-14.7% | $33.9M+39.3% | $24.3M-20.3% | $30.5M |
| Inventory | $364.4M+0.6% | $362.3M+2.1% | $354.7M+2.3% | $346.7M+7.6% | $322.4M0.0% | $322.3M+1.2% | $318.3M-2.3% | $325.8M |
| Accounts Receivable | $224.9M-3.9% | $234.1M+5.9% | $221.1M-7.0% | $237.7M-0.6% | $239.2M-0.9% | $241.5M-0.3% | $242.3M+5.2% | $230.2M |
| Goodwill | $806.9M0.0% | $806.9M+0.2% | $805.7M0.0% | $805.4M-0.1% | $806.2M0.0% | $806.3M-0.1% | $806.8M-1.0% | $815.1M |
| Total Liabilities | $1.3B-0.9% | $1.3B+0.4% | $1.3B-1.8% | $1.3B-4.3% | $1.4B-3.5% | $1.5B-0.8% | $1.5B-4.2% | $1.5B |
| Current Liabilities | $314.7M+6.7% | $294.8M+4.1% | $283.1M+1.8% | $278.1M+4.4% | $266.4M-8.6% | $291.4M-6.2% | $310.7M-17.4% | $376.3M |
| Long-Term Debt | $853.0M-3.2% | $881.1M-1.2% | $891.4M-1.5% | $905.1M-6.2% | $965.2M-2.5% | $990.1M+1.7% | $973.1M+3.3% | $942.2M |
| Total Equity | $1.0B+0.5% | $1.0B+2.6% | $977.6M+1.6% | $962.7M+9.2% | $881.8M+3.2% | $854.7M+2.5% | $834.2M+4.8% | $796.2M |
| Retained Earnings | $572.0M-0.6% | $575.4M+2.7% | $560.1M0.0% | $560.3M+14.4% | $489.9M+5.1% | $466.1M+3.0% | $452.5M+6.3% | $425.6M |
CNMD Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $53.7M+84.3% | $29.1M-29.9% | $41.5M-4.2% | $43.3M+0.1% | $43.3M+48.7% | $29.1M-48.4% | $56.4M+22.3% | $46.1M |
| Capital Expenditures | $5.2M-9.5% | $5.7M+51.6% | $3.8M-6.5% | $4.0M+12.5% | $3.6M+76.4% | $2.0M-58.1% | $4.9M-10.0% | $5.4M |
| Free Cash Flow | $48.5M+107.2% | $23.4M-38.0% | $37.8M-3.9% | $39.3M-1.1% | $39.7M+46.6% | $27.1M-47.4% | $51.5M+26.5% | $40.7M |
| Investing Cash Flow | -$5.2M+9.5% | -$5.7M-95.6% | -$2.9M+27.5% | -$4.0M-12.5% | -$3.6M-76.4% | -$2.0M+58.1% | -$4.9M+10.0% | -$5.4M |
| Financing Cash Flow | -$43.5M-64.1% | -$26.5M+6.6% | -$28.4M+44.4% | -$51.1M-15.8% | -$44.1M-159.1% | -$17.0M+71.0% | -$58.8M-57.9% | -$37.2M |
| Dividends Paid | $6.2M0.0% | $6.2M+0.1% | $6.2M0.0% | $6.2M+0.3% | $6.2M+0.1% | $6.2M+0.1% | $6.1M+0.1% | $6.1M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CNMD Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.2%-5.9pp | 55.0%-0.3pp | 55.3%-2.0pp | 57.3%+2.0pp | 55.3%+0.3pp | 55.1%-0.6pp | 55.7%+0.5pp | 55.2% |
| Operating Margin | 3.5%-7.6pp | 11.2%+6.2pp | 5.0%-10.2pp | 15.2%+1.0pp | 14.2%+3.0pp | 11.2%-4.1pp | 15.3%+5.4pp | 10.0% |
| Net Margin | 0.9%-5.4pp | 6.3%+4.4pp | 1.9%-7.9pp | 9.8%+0.7pp | 9.0%+2.7pp | 6.3%-3.8pp | 10.1%+4.9pp | 5.2% |
| Return on Equity | 0.3%-1.9pp | 2.1%+1.5pp | 0.6%-2.9pp | 3.5%+0.1pp | 3.4%+1.1pp | 2.3%-1.7pp | 4.0%+2.0pp | 2.0% |
| Return on Assets | 0.1%-0.8pp | 0.9%+0.7pp | 0.3%-1.2pp | 1.5%+0.1pp | 1.3%+0.5pp | 0.9%-0.6pp | 1.4%+0.8pp | 0.7% |
| Current Ratio | 2.10-0.1 | 2.23-0.0 | 2.26-0.0 | 2.30-0.0 | 2.34+0.2 | 2.18+0.2 | 1.98+0.3 | 1.66 |
| Debt-to-Equity | 0.85-0.0 | 0.88-0.0 | 0.91-0.0 | 0.94-0.2 | 1.09-0.1 | 1.160.0 | 1.17-0.0 | 1.18 |
| FCF Margin | 14.3%+7.5pp | 6.8%-4.9pp | 11.8%+0.4pp | 11.4%-0.6pp | 12.0%+3.3pp | 8.7%-7.1pp | 15.8%+2.4pp | 13.4% |
Similar Companies
Frequently Asked Questions
What is Conmed Corp's annual revenue?
Conmed Corp (CNMD) reported $1.4M in total revenue for fiscal year 2025. This represents a -99.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Conmed Corp's revenue growing?
Conmed Corp (CNMD) revenue declined by 99.9% year-over-year, from $1.3B to $1.4M in fiscal year 2025.
Is Conmed Corp profitable?
Yes, Conmed Corp (CNMD) reported a net income of $47K in fiscal year 2025, with a net profit margin of 3.4%.
What is Conmed Corp's earnings per share (EPS)?
Conmed Corp (CNMD) reported diluted earnings per share of $1.51 for fiscal year 2025. This represents a -64.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Conmed Corp's EBITDA?
Conmed Corp (CNMD) had EBITDA of $120K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Conmed Corp have?
As of fiscal year 2025, Conmed Corp (CNMD) had $41K in cash and equivalents against $40K in long-term debt.
What is Conmed Corp's gross margin?
Conmed Corp (CNMD) had a gross margin of 54.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Conmed Corp's operating margin?
Conmed Corp (CNMD) had an operating margin of 7.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Conmed Corp's net profit margin?
Conmed Corp (CNMD) had a net profit margin of 3.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Conmed Corp pay dividends?
Yes, Conmed Corp (CNMD) paid $0.80 per share in dividends during fiscal year 2025.
What is Conmed Corp's return on equity (ROE)?
Conmed Corp (CNMD) has a return on equity of 4.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Conmed Corp's free cash flow?
Conmed Corp (CNMD) generated $151K in free cash flow during fiscal year 2025. This represents a -99.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Conmed Corp's operating cash flow?
Conmed Corp (CNMD) generated $171K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Conmed Corp's total assets?
Conmed Corp (CNMD) had $2.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Conmed Corp's capital expenditures?
Conmed Corp (CNMD) invested $20K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Conmed Corp spend on research and development?
Conmed Corp (CNMD) invested $56K in research and development during fiscal year 2025.
How many shares does Conmed Corp have outstanding?
Conmed Corp (CNMD) had 31M shares outstanding as of fiscal year 2025.
What is Conmed Corp's current ratio?
Conmed Corp (CNMD) had a current ratio of 2.14 as of fiscal year 2025, which is generally considered healthy.
What is Conmed Corp's debt-to-equity ratio?
Conmed Corp (CNMD) had a debt-to-equity ratio of 0.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Conmed Corp's return on assets (ROA)?
Conmed Corp (CNMD) had a return on assets of 2.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Conmed Corp's Altman Z-Score?
Conmed Corp (CNMD) has an Altman Z-Score of 602.12, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Conmed Corp's Piotroski F-Score?
Conmed Corp (CNMD) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Conmed Corp's earnings high quality?
Conmed Corp (CNMD) has an earnings quality ratio of 3.63x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Conmed Corp cover its interest payments?
Conmed Corp (CNMD) has an interest coverage ratio of 3.3x, meaning it can adequately cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Conmed Corp?
Conmed Corp (CNMD) scores 46 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.